Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PALISADE BIO, INC. (PALI)

Palisade Bio Q1 net loss widens to $9.6 million; cash $132.6 million

Negative Impact 3 of 5 earnings Written later

Palisade Bio reported a first-quarter 2026 net loss of $9.6 million, up from $2.2 million a year earlier, as research and development and general and administrative expenses rose sharply. The company had $132.6 million in cash and cash equivalents at March 31, 2026, and said it expects that cash to fund operations through its Phase 2 ulcerative colitis and Crohn's disease readouts, but the filing reports no revenue and a much larger loss for shareholders.

Key points

  • Net loss was $9.6 million, or $0.05 per share, for the three months ended March 31, 2026, versus $2.2 million, or $0.47 per share, a year earlier.
  • Research and development expenses rose to $6.4 million from $1.0 million; general and administrative expenses rose to $4.4 million from $1.4 million.
  • Cash and cash equivalents were $132.6 million at March 31, 2026, down from $133.4 million at December 31, 2025.
  • Phase 2 ulcerative colitis trial initiation is targeted for Q3 2026, and the Phase 2 UC readout is expected in 2H 2027.

The filing

CompanyPALISADE BIO, INC. (PALI)
Form8-K, current report
Filed with the SECMay 12, 2026, 4:14 PM ET
Accession number0001357459-26-000011

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.